Real-world utilization and acceptance of biosimilar bevacizumab in metastatic colorectal cancer in India

L. Patel, Shreekant Sharma, D. Bunger
{"title":"Real-world utilization and acceptance of biosimilar bevacizumab in metastatic colorectal cancer in India","authors":"L. Patel, Shreekant Sharma, D. Bunger","doi":"10.18203/2349-3259.ijct20222626","DOIUrl":null,"url":null,"abstract":"Background: To describe the patient characteristics and usage pattern of biosimilar bevacizumab for the treatment of metastatic colorectal cancer (mCRC) in India.Methods: This real-world, retrospective analysis included adult patients receiving biosimilar bevacizumab between April 2021 and March 2022.Results: A total of 1125 patients with mCRC who received biosimilar bevacizumab-based chemotherapy were included. The mean age at diagnosis was 57.8 years. Majority of the patients were males (71%) and belonged to the age groups of 41-76 years. The primary tumor site was right colon (52.6%) followed by left colon (29.2%) and rectum (17.3%), and the tumor grade was reported as high in most (88.7%) of the patients. Majority of patients received biosimilar bevacizumab-based chemotherapy as first-line therapy (61.3%), followed by second-line (31.9%) and third-line therapy (6.8%). In combination with biosimilar bevacizumab, FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) was the most commonly administered regimen (42.9%), followed by CAPOX (capecitabine and oxaliplatin, 26.5%) and FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan, 22.8%).Conclusions: Biosimilar bevacizumab-based chemotherapy is being widely used in real‑world clinical setting in India for the management of patients with mCRC.","PeriodicalId":13787,"journal":{"name":"International Journal of Clinical Trials","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18203/2349-3259.ijct20222626","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: To describe the patient characteristics and usage pattern of biosimilar bevacizumab for the treatment of metastatic colorectal cancer (mCRC) in India.Methods: This real-world, retrospective analysis included adult patients receiving biosimilar bevacizumab between April 2021 and March 2022.Results: A total of 1125 patients with mCRC who received biosimilar bevacizumab-based chemotherapy were included. The mean age at diagnosis was 57.8 years. Majority of the patients were males (71%) and belonged to the age groups of 41-76 years. The primary tumor site was right colon (52.6%) followed by left colon (29.2%) and rectum (17.3%), and the tumor grade was reported as high in most (88.7%) of the patients. Majority of patients received biosimilar bevacizumab-based chemotherapy as first-line therapy (61.3%), followed by second-line (31.9%) and third-line therapy (6.8%). In combination with biosimilar bevacizumab, FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) was the most commonly administered regimen (42.9%), followed by CAPOX (capecitabine and oxaliplatin, 26.5%) and FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan, 22.8%).Conclusions: Biosimilar bevacizumab-based chemotherapy is being widely used in real‑world clinical setting in India for the management of patients with mCRC.
贝伐单抗生物仿制药在印度转移性结直肠癌中的实际应用和接受度
背景:描述印度生物仿制药贝伐单抗治疗转移性结直肠癌(mCRC)的患者特征和使用模式。方法:这项现实世界的回顾性分析包括2021年4月至2022年3月期间接受贝伐单抗生物仿制药治疗的成年患者。结果:共纳入1125例接受贝伐单抗生物仿制药化疗的mCRC患者。平均诊断年龄为57.8岁。患者以男性为主(71%),年龄在41 ~ 76岁之间。原发部位为右结肠(52.6%),其次为左结肠(29.2%)和直肠(17.3%),多数患者肿瘤分级高(88.7%)。大多数患者接受以贝伐单抗为基础的生物类似药化疗作为一线治疗(61.3%),其次是二线(31.9%)和三线治疗(6.8%)。与生物类似药贝伐单抗联合使用时,FOLFOX(叶酸、5-氟尿嘧啶和奥沙利铂)是最常用的方案(42.9%),其次是CAPOX(卡培他滨和奥沙利铂,26.5%)和FOLFIRI(叶酸、5-氟尿嘧啶和伊立替康,22.8%)。结论:基于贝伐单抗的生物类似药化疗在印度的临床环境中被广泛应用于mCRC患者的治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信